Research from ACF Equity Research, ACF Equity Research

ACF Equity Research

Research from ACF Equity Research

Accuracy | Clarity | Foresight

ACF was set up to improve the effectiveness of capital markets for smaller and mid-sized companies. The majority of jobs are created by smaller companies not global companies. If we can help improve companies use of capital markets more projects will be completed, more jobs created, more global GDP grown, which in turn helps create more resources for education, leading to equality and opportunity for those who are still oppressed by ignorance and poverty.

ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.

We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.

Our independent research is designed to educate our professional investor readers about your company, with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.

We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.

Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.

Equity Bottom-Up

Coeptis Therapeutics Holdings / Equity Bottom-Up

<ul>
<li>Deverra deal adds two patented assets to COEP product pipeline;</li>
<li>Reduces COEP risk profile and so contributes to our valuation range;</li>
<li>DVX201 - Unmodified NKC therapy from pooled donor CD34+ cells.</li>
</ul>


Deverra deal adds two patented assets to COEP product pipeline;
Reduces COEP risk profile and so contributes to our valuation range;
DVX201 - Unmodified NKC therapy from pooled donor CD34+ cells.


Coeptistx (COEP) Deverra Deal Flash Note 21082023

<ul>
<li>C&amp;CE 1Q23A $2.1m, burn 1Q $1.6m, S-1MEF filed for raise</li>
<li>YE22A Opex $34.2m vs. $14.1 y/y, Δ is redemptions/merger costs</li>
<li>Warrants booked as liabilities (SEC de-SPAC ruling Apr 12, 2021)</li>
</ul>


C&amp;CE 1Q23A $2.1m, burn 1Q $1.6m, S-1MEF filed for raise
YE22A Opex $34.2m vs. $14.1 y/y, Δ is redemptions/merger costs
Warrants booked as liabilities (SEC de-SPAC ruling Apr 12, 2021)


Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023

<ul>
<li>Binding exclusivity to acquire or license Deverra Therapeutics’ platform asset </li>
<li>CAR-T + GEAR COEP platforms could plug into Deverra platform</li>
<li>Other key assets – 2x FDA approved PI INDs for CD34+ NK Cells.</li>
</ul>


Binding exclusivity to acquire or license Deverra Therapeutics’ platform asset 
CAR-T + GEAR COEP platforms could plug into Deverra platform
Other key assets – 2x FDA approved PI INDs for CD34+ NK Cells.


Coeptistx (COEP) Deverra Deal Flash Note 20042023

<div>Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially novel products targeting CD38+ related unmet need and solid tumor cancers. The up list to Nasdaq via the SPAC Bull Horn Holdings (BHSE) is a key milestone leaving COEP with 19,516,839 shares in issue, better liquidity and greater access to capital needed to advance its pipeline. We assess that there are multiple value drivers within COEP, including its two lead candidates (GEAR-NK and CD38+-Diagnostic) along with its IP rights to its solid tumor targeting SNAP-CAR platform (‘universal wrench’). If proven clinically, COEP could significantly improve treatment outcomes in CD38+ cancers and in a range of solid tumors, e.g., breast and ovarian cancers.</div>

Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially novel products targeting CD38+ related unmet need and solid tumor cancers. The up list to Nasdaq via the SPAC Bull Horn Holdings (BHSE) is a key milestone leaving COEP with 19,516,839 shares in issue, better liquidity and greater access to capital needed to advance its pipeline. We assess that there are multiple value drivers within COEP, including its two lead candidates (GEAR-NK and CD38+-Diagnostic) along with its IP rights to its solid tumor targeting SNAP-CAR platform (‘universal wrench’). If proven clinically, COEP could significantly improve treatment outcomes in CD38+ cancers and in a range of solid tumors, e.g., breast and ovarian cancers.

Coeptis Therapeutics Inc. (COEP) Initiation Note ACF Equity Research 16112022

<div>Coeptis Therapeutics Inc. (OTC: COEP) is a biopharmaceutical company</div>
<div>developing innovative cell therapy platforms for fighting cancer. The product</div>
<div>portfolio comprises - cell therapy technology (CD38-GEAR-NK); in vitro</div>
<div>diagnostic (CD38-Diagnostic) targeting CD38+ cancers; and recently COEP</div>
<div>signed an exclusive license agreement with the University of Pittsburgh</div>
<div>conveying IP rights to its solid tumor targeting SNAP-CAR platform; COEP’s</div>
<div>strategy is to develop its product portfolio to license to and partner with</div>
<div>large-cap pharma corps. COEP has uplisted to Nasdaq as a function of the</div>
<div>previously announced merger agreement with special purpose acquisition</div>
<div>company (SPAC), Bull Horn Holdings.</div>

Coeptis Therapeutics Inc. (OTC: COEP) is a biopharmaceutical company
developing innovative cell therapy platforms for fighting cancer. The product
portfolio comprises - cell therapy technology (CD38-GEAR-NK); in vitro
diagnostic (CD38-Diagnostic) targeting CD38+ cancers; and recently COEP
signed an exclusive license agreement with the University of Pittsburgh
conveying IP rights to its solid tumor targeting SNAP-CAR platform; COEP’s
strategy is to develop its product portfolio to license to and partner with
large-cap pharma corps. COEP has uplisted to Nasdaq as a function of the
previously announced merger agreement with special purpose acquisition
company (SPAC), Bull Horn Holdings.

Coeptis Therapeutics Inc. (COEP) Core Investment Case ACF Equity Research 01112022

United States

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Coeptis Therapeutics Holdings (COEP US)

Coeptistx (COEP) Deverra Deal Flash Note 21082023

COEP’s exclusive license deal with Deverra for DVX201, two products ’54’ & ‘16’ provides access to Deverra’s no-HLA-matching platform asset.

ACF Equity Research

Coeptis Therapeutics Inc. (COEP) YE22 1Q23 & DeSPAC 29062023

COEP is a pre-clinical stage bio-pharma corp targeting CD38+ related unmet need and solidtumor cancers.YE22A results show wash through of the SPAC...

ACF Equity Research

Coeptistx (COEP) Deverra Deal Flash Note 20042023

Coeptis Therapeutics Inc., a pre-clinical stagebiopharmaceutical Corp, announced an exclusive term sheet to acquire or license Deverra...

ACF Equity Research

Coeptis Therapeutics Inc. (COEP) Initiation Note ACF Equity Research 16112022

Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially...

ACF Equity Research

Coeptis Therapeutics Inc. (COEP) Core Investment Case ACF Equity Research 01112022

Coeptis Therapeutics Inc. (OTC: COEP) is a biopharmaceutical company developing innovative cell therapy platforms for fighting cancer. The...

ACF Equity Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)